1. Pink Sheet
  2. >>Vaccines

Pfizer’s Arms-Length Attitude Toward Operation Warp Speed: Two Views On How It Worked

 
• By Cathy Kelly

Pfizer CEO Albert Bourla and HHS deputy chief of staff Paul Mango offer their perspectives in separate interviews promoting new books about the campaign to develop vaccines against COVID-19.

Tensions developed Between Pfizer And The Trump Administration Over Who Made Final decisions as part of the effort to accelerate COVID vaccines • Source: Alamy

Pfizer Inc. CEO Albert Bourla suggested in a recent interview that the Trump Administration’s Operation Warp Speed team may have put obstacles in the company’s way, or at least did not rush to clear them, because Pfizer had opted not to accept development or production funding from the federal government.

Among the firms that entered into government contracts for COVID-19 vaccines, Pfizer was the only one that did not take funding for development and manufacturing, only for purchases of the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Vaccines

More from Pink Sheet

EMA Official Clarifies Benefits And Limitations Of Innovation Pathways

 
• By Eliza Slawther

A European Medicines Agency official provided an overview and update of the support the EMA offers developers of innovative products and discussed, among other things, its Innovation Task Force, Quality Innovation Group and a scientific advice pilot for clinical trials.

EU Emergency Response Authority Needs Bigger Budget To Address Health Threats, Says Industry

 
• By Eliza Slawther

The EU must renew the mandate of its Health Emergency Response Authority to support medicine stockpiles and enable agile manufacturing to combat antimicrobial resistance and chemical, biological, radiological and nuclear threats, says trade organization EUCOPE.